Literature DB >> 22698627

National Comprehensive Cancer Network practice guidelines 2011: Need for more accurate recommendations for pelvic lymph node dissection in prostate cancer.

Firas Abdollah1, Maxine Sun, Nazareno Suardi, Andrea Gallina, Umberto Capitanio, Marco Bianchi, Manuela Tutolo, Niccolò Passoni, Pierre I Karakiewicz, Patrizio Rigatti, Francesco Montorsi, Alberto Briganti.   

Abstract

PURPOSE: The 2011 NCCN (National Comprehensive Cancer Network) guidelines for prostate cancer recommend pelvic lymph node dissection at radical prostatectomy in all individuals with a nomogram predicted lymph node invasion probability of 2% or greater. We examined the ability of these guidelines to correctly predict lymph node invasion in patients treated with extended pelvic lymph node dissection.
MATERIALS AND METHODS: We examined 3,064 consecutive patients treated with radical prostatectomy and extended pelvic lymph node dissection between 2000 and 2010. We formally validated the NCCN guideline nomogram using discrimination, calibration and decision curve analysis as benchmarks. Moreover the performance characteristics of the 2% nomogram cutoff as well as other cutoff values (range 1% to 10%) were tested.
RESULTS: Overall 10.0% of patients had lymph node invasion. The discrimination accuracy of the NCCN guideline nomogram was 79.8%, with a maximum underestimation of the lymph node invasion risk of 41.2%. On decision curve analysis the NCCN nomogram fared better than not performing pelvic lymph node dissection in all patients. However, in the prediction range between 0% and 9% the nomogram did not fare better than performing pelvic lymph node dissection in all patients. The use of the 2% cutoff would allow the avoidance of 49.3% of pelvic lymph node dissections, at the cost of missing 20.3% of patients with lymph node invasion.
CONCLUSIONS: The NCCN nomogram tends to significantly underestimate the real lymph node invasion rate. Moreover the use of the currently recommended cutoff of 2% to trigger pelvic lymph node dissection might not be appropriate.
Copyright © 2012 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22698627     DOI: 10.1016/j.juro.2012.03.129

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Current status of pelvic lymph node dissection in prostate cancer.

Authors:  Ilija Aleksic; Tyler Luthringer; Vladimir Mouraviev; David M Albala
Journal:  J Robot Surg       Date:  2013-12-11

Review 2.  How to minimize lymphoceles and treat clinically symptomatic lymphoceles after radical prostatectomy.

Authors:  Hak J Lee; Christopher J Kane
Journal:  Curr Urol Rep       Date:  2014-10       Impact factor: 3.092

3.  Detection of Lymph Node Metastases with SERRS Nanoparticles.

Authors:  Massimiliano Spaliviero; Stefan Harmsen; Ruimin Huang; Matthew A Wall; Chrysafis Andreou; James A Eastham; Karim A Touijer; Peter T Scardino; Moritz F Kircher
Journal:  Mol Imaging Biol       Date:  2016-10       Impact factor: 3.488

4.  Outcomes and complications of pelvic lymph node dissection during robotic-assisted radical prostatectomy.

Authors:  Michael A Liss; Kerrin Palazzi; Sean P Stroup; Ramzi Jabaji; Omer A Raheem; Christopher J Kane
Journal:  World J Urol       Date:  2013-03-20       Impact factor: 4.226

5.  National Comprehensive Cancer Network (NCCN) risk classification in predicting biochemical recurrence after radical prostatectomy: a retrospective cohort study in Chinese prostate cancer patients.

Authors:  Hua Xu; Yao Zhu; Bo Dai; Ding-Wei Ye
Journal:  Asian J Androl       Date:  2018 Nov-Dec       Impact factor: 3.285

6.  Analyzing EGFR mutations and their association with clinicopathological characteristics and prognosis of patients with lung adenocarcinoma.

Authors:  Xiuzhi Zhou; Li Cai; Junjie Liu; Xiaomin Hua; Ying Zhang; Huilin Zhao; Bin Wang; Boqing Li; Pengzhou Gai
Journal:  Oncol Lett       Date:  2018-05-09       Impact factor: 2.967

7.  Barriers to surveillance imaging adherence in early-staged lung cancer.

Authors:  Ian C Bostock; Wayne Hofstetter; Reza Mehran; Ravi Rajaram; David Rice; Boris Sepesi; Stephen Swisher; Ara Vaporciyan; Garrett Walsh; Mara B Antonoff
Journal:  J Thorac Dis       Date:  2021-12       Impact factor: 2.895

Review 8.  Raman Spectroscopy in Prostate Cancer: Techniques, Applications and Advancements.

Authors:  Fortis Gaba; William J Tipping; Mark Salji; Karen Faulds; Duncan Graham; Hing Y Leung
Journal:  Cancers (Basel)       Date:  2022-03-17       Impact factor: 6.575

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.